3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Lung Neoplasms
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
9
Cetuximab
5
Surveys and Questionnaires
4
Cisplatin
4
dostarlimab
2
abemaciclib
2
Standard of Care
2
Docetaxel
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
ulixertinib
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
tipifarnib
1
ribociclib
1
repotrectinib
1
patritumab deruxtecan
1
palbociclib
1
olaparib
1
nimotuzumab
1
monalizumab
1
ibrutinib
1
fludarabine
1
exemestane
1
entrectinib
1
ebselen
1
durvalumab
1
disitamab vedotin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
monalizumab
×
30 days
×
Clear all
NCT04590963
2026-06-01
INTERLINK-1
AstraZeneca
Phase 3
Active not recruiting
370 enrolled
21 charts